The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen
 
Li Zhou
No Relationships to Disclose
 
Kaiwei Yang
No Relationships to Disclose
 
Shun Zhang
No Relationships to Disclose
 
Huayan Xu
No Relationships to Disclose
 
Xieqiao Yan
No Relationships to Disclose
 
Siming Li
No Relationships to Disclose
 
Juan Li
No Relationships to Disclose
 
Chuanliang Cui
No Relationships to Disclose
 
Zhihong Chi
No Relationships to Disclose
 
Lu Si
Honoraria - MSD; Novartis; Oriengene; Roche China; Shanghai Junshi Biosciences
 
Bixia Tang
No Relationships to Disclose
 
Lili Mao
Honoraria - MSD; Novartis; Shanghai Junshi BioSciences
Research Funding - MSD
 
Bin Lian
No Relationships to Disclose
 
Xuan Wang
Consulting or Advisory Role - Oriengene
 
Xue Bai
No Relationships to Disclose
 
Zhisong He
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere